These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 30056728)
1. Advances in chemotherapy for HER2-negative metastatic breast cancer. Mukai H; Ito M Chin Clin Oncol; 2018 Jun; 7(3):26. PubMed ID: 30056728 [TBL] [Abstract][Full Text] [Related]
2. Advances in anti-HER2 therapy in metastatic breast cancer. Yao M; Fu P Chin Clin Oncol; 2018 Jun; 7(3):27. PubMed ID: 30056729 [TBL] [Abstract][Full Text] [Related]
3. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer. Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139 [TBL] [Abstract][Full Text] [Related]
4. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. Hartkopf AD; Huober J; Volz B; Nabieva N; Taran FA; Schwitulla J; Overkamp F; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lux MP; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Wimberger P; Hielscher C; Geberth M; Fersis N; Abenhardt W; Kurbacher C; Wuerstlein R; Thomssen C; Untch M; Fasching PA; Janni W; Fehm TN; Wallwiener D; Brucker SY; Schneeweiss A Breast; 2018 Feb; 37():42-51. PubMed ID: 29100043 [TBL] [Abstract][Full Text] [Related]
5. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer. Farhat F; Kattan JG; Ghosn M Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339 [TBL] [Abstract][Full Text] [Related]
6. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T; Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767 [TBL] [Abstract][Full Text] [Related]
7. Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study. Manso L; Palomo AG; Pérez Carrión R; Cassinello J; Gallegos Sancho I; Chacón López-Muñiz I; Olier C; Fernández-Aramburo A; Llorca C; González X; Llorente R; Torregrosa D; Álvarez I; Gálve E; Bueno C; Garau I; García MJ; González-Santiago S; Ballesteros AI; Blanco E; Galán A; González S; Perelló A; Cortés-Funes H; Grávalos C Anticancer Res; 2015 Dec; 35(12):6941-50. PubMed ID: 26637920 [TBL] [Abstract][Full Text] [Related]
8. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. Del Mastro L; Lambertini M; Bighin C; Levaggi A; D'Alonzo A; Giraudi S; Pronzato P Expert Rev Anticancer Ther; 2012 Nov; 12(11):1391-405. PubMed ID: 23072512 [TBL] [Abstract][Full Text] [Related]
9. The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective. Gupta S; Zhang J; Jerusalem G Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):929-40. PubMed ID: 25130198 [TBL] [Abstract][Full Text] [Related]
10. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748 [TBL] [Abstract][Full Text] [Related]
11. First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces? Fabi A; Malaguti P; Vari S; Cognetti F J Exp Clin Cancer Res; 2016 Jun; 35():104. PubMed ID: 27357210 [TBL] [Abstract][Full Text] [Related]
12. Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe. Gao S; Barber B; Schabert V; Ferrufino C Curr Med Res Opin; 2012 Jul; 28(7):1111-8. PubMed ID: 22587480 [TBL] [Abstract][Full Text] [Related]
13. Targeting HER2 in Advanced Breast Cancer. Zhu X; Joy AA Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634 [TBL] [Abstract][Full Text] [Related]
14. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer. Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351 [TBL] [Abstract][Full Text] [Related]
15. New developments in metastatic breast cancer: integrating recent data into clinical practice. Perez EA; Rugo HS; Vahdat LT Clin Adv Hematol Oncol; 2013; 11(10 Suppl 16):1-18; quiz 19. PubMed ID: 24892840 [TBL] [Abstract][Full Text] [Related]
16. Current and future anti-HER2 therapy in breast cancer. Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M J BUON; 2013; 18(1):4-16. PubMed ID: 23613383 [TBL] [Abstract][Full Text] [Related]
17. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients. Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N J BUON; 2013; 18(3):585-93. PubMed ID: 24065468 [TBL] [Abstract][Full Text] [Related]
18. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054 [TBL] [Abstract][Full Text] [Related]
19. HER2-positive breast cancer: Current and new therapeutic strategies. Escrivá-de-Romaní S; Arumí M; Bellet M; Saura C Breast; 2018 Jun; 39():80-88. PubMed ID: 29631097 [TBL] [Abstract][Full Text] [Related]
20. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer. Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]